SCHEMBL195157

SCHEMBL195157

CCCCCCCCc1ccc(S(=O)(=O)O)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.66
ALDH1A1 P00352 3/20 0.58
ESR1 P03372 2/20 0.58
ADRA2A P08913 2/20 0.58
ADORA3 P0DMS8 2/20 0.58
TACR2 P21452 2/20 0.58
SLC6A2 P23975 2/20 0.58
SLC6A4 P31645 2/20 0.58
SLC6A3 Q01959 2/20 0.58
KDM4E B2RXH2 1/20 0.58
LMNA P02545 1/20 0.58
SHBG P04278 1/20 0.58
TP53 P04637 1/20 0.58
CYP3A4 P08684 1/20 0.58
HSPD1 P10809 1/20 0.58
ADRB3 P13945 1/20 0.58
HTR2C P28335 1/20 0.58
HSPE1 P61604 1/20 0.58
HIF1A Q16665 1/20 0.58
TST Q16762 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4532142 1.00 CA2 (0.66) CA2ALDH1A1ESR1ADRA2AADORA3
SCHEMBL4527877 1.00 CA2 (0.66) CA2ALDH1A1ESR1ADRA2AADORA3
SCHEMBL4203952 1.00 CA2 (0.66) CA2ALDH1A1ESR1ADRA2AADORA3
SCHEMBL1301381 1.00 CA2 (0.66) CA2ALDH1A1ESR1ADRA2AADORA3
SCHEMBL4534627 1.00 CA2 (0.66) CA2ALDH1A1ESR1ADRA2AADORA3
SCHEMBL974537 1.00 CA2 (0.66) CA2ALDH1A1ESR1ADRA2AADORA3
SCHEMBL2733171 1.00 CA2 (0.66) CA2ALDH1A1ESR1ADRA2AADORA3
SCHEMBL4532942 1.00 CA2 (0.66) CA2ALDH1A1ESR1ADRA2AADORA3
SCHEMBL4528217 1.00 CA2 (0.66) CA2ALDH1A1ESR1ADRA2AADORA3
SCHEMBL197275 1.00 CA2 (0.66) CA2ALDH1A1ESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 652 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034124-A1 NOVEL SALTS AND CRYSTALS INTRA CELLULAR THERAPIES INC (US) 2026-02-05 US claimed
EP-4561569-A2 NOVEL SALTS AND CRYSTALS Intra-Cellular Therapies, Inc. (US) 2025-06-04 EP claimed
CN-113785243-B Composition for resist pattern metallization process 日产化学株式会社 2025-05-02 CN claimed
EP-3605097-B1 SUBSTANCE THAT PREVENTS ANTIGEN-ANTIBODY REACTION INHIBITION BY BODY FLUID NH FOODS LTD (JP) 2024-11-13 EP claimed
US-12012540-B2 Compositions and methods for selectively etching silicon nitride films ENTEGRIS, INC. (US) 2024-06-18 US claimed
US-20240131231-A1 NITRIC OXIDE-RELEASING COMPOSITIONS AND APPLICATIONS THEREOF NATIONAL INSTITUTES OF HEALTH 2024-04-25 US claimed
EP-4347744-A1 COMPOSITIONS AND METHODS FOR SELECTIVELY ETCHING SILICON NITRIDE FILMS Entegris, Inc. (US) 2024-04-10 EP claimed
WO-2024030835-A2 NOVEL SALTS AND CRYSTALS INTRA-CELLULAR THERAPIES, INC. (US) 2024-02-08 WO claimed
CN-117460805-A Composition and method for selectively etching silicon nitride film 恩特格里斯公司 2024-01-26 CN claimed
EP-4288123-A1 NITRIC OXIDE-RELEASING COMPOSITIONS AND APPLICATIONS THEREOF University of Georgia Research Foundation, Inc. (US) 2023-12-13 EP claimed
EP-0554006-B1 Polyunsaturated diazonium compounds AGFA GEVAERT NV (BE) 1999-04-28 EP claimed
WO-1998008919-A9 NOVEL WATER SOLUBLE METAL WORKING FLUIDS 1998-05-28 WO claimed
WO-1998008919-A2 NOVEL WATER SOLUBLE METAL WORKING FLUIDS SOLUTIA INC. (US) 1998-03-05 WO claimed
EP-0825618-A2 Electrically-conductive polymer and production method thereof, and solid-electrolytic capacitor NEC CORPORATION (JP) 1998-02-25 EP claimed
US-5500668-A INK JET PRINTING XEROX CORPORATION (US) 1996-03-19 US claimed
EP-0233072-B1 IMPROVEMENTS IN OR RELATING TO RADIATION SENSITIVE MATERIAL E.I. du Pont de Nemours and Company (US) 1992-09-02 EP claimed
EP-0064338-B1 COATING COMPOSITIONS CAPABLE OF CURING AT ROOM TEMPERATURE BASED ON A HYDROXYL GROUP-CONTAINING ADDITION POLYMER, AN ALKYLATED MELAMINE-FORMALDEHYDE CROSSLINKING AGENT AND A BLEND OF SPECIFIED ALKYLATED ARYLSULPHONIC ACIDS AS CATALYST IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-07-25 EP claimed
US-4452945-A HYDROXYL GROUP CONTAINING ADDITION POLYMER AND ALKYLATED MELAMINE-FORMALDEHYDE CROSSLINKING AGENT IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-06-05 US claimed
EP-0064338-A1 Coating compositions capable of curing at room temperature based on a hydroxyl group-containing addition polymer, an alkylated melamine-formaldehyde crosslinking agent and a blend of specified alkylated arylsulphonic acids as catalyst IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-11-10 EP claimed
US-4171459-A Manufacture of α-naphthol BASF AKTIENGESELLSCHAFT (DE) 1979-10-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034124-A1 NOVEL SALTS AND CRYSTALS SLC6A4, SLC6A3, HTR2A CA2 1503/4885ALDH1A1 1599/4885ESR1 649/4885
US-20240131231-A1 NITRIC OXIDE-RELEASING COMPOSITIONS AND APPLICATIONS THEREOF NOS2, NOS1, NOS3 CA2 3461/4885ALDH1A1 2686/4885ESR1 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.